Urokinase plasminogen activator (uPA) plays an important role in the progression of several malignancies including breast cancer. We have identified a noncompetitive antagonist of the uPA-uPAR interaction derived from a nonreceptor binding region of uPA (amino acids 136 -143). This 8-mer capped peptide (Å6) inhibited breast cancer cell invasion and endothelial cell migration in a dose-dependent manner in vitro without altering cell doubling time. Intraperitoneal administration of Å6 resulted in a significant inhibition of tumor growth and suppressed the development of lymph node metastases in several models of breast cancer cell growth and metastasis. Large areas of tumor necrosis and extensive positive staining by TUNEL were observed on histological and immunohistochemical analysis of experimental tumor sections from Å6-treated animals. Å6 treatment also resulted in a decrease in factor VIII-positive tumor microvessel hot-spots. These results identify a new epitope in uPA that is involved in the uPA-uPAR interaction and indicate that an antagonist based on this epitope is able to inhibit tumor progression by modulating the tumor microenvironment in the absence of direct cytotoxic effects in vivo.
The urokinase plasminogen activator (uPA) system has been implicated in the progression, metastasis, and angiogenesis of numerous solid tumors (1) (2) (3) (4) . Expression of the components of the uPA system and its specific cell-surface receptor (uPAR) often increases with disease progression and is correlated with poor prognosis and outcome in patients (5, 6) . The expression of uPA and uPAR is not restricted to tumor cells alone since other tumorassociated cells, such as angiogenic endothelial cells, macrophages, and fibroblasts have been demonstrated to express one or both components of this system (7) (8) (9) . Moreover, the pattern of expression and the cells responsible for this expression may differ depending on the type and stage. Expression of uPA and uPAR is associated with tumor progression and is often localized to the leading, invasive edge of a tumor (10, 11) .
The uPA system has pleiotropic functions in tumor progression whereby several pathways may be temporally activated when uPA binds to uPAR. Various intracellular signaling pathways are initiated when uPA binds to uPAR including the up-regulation of oncogene expression, stimulation of cell adhesion, regulation of chemotaxis, and activation of the MAP kinase pathway (12) (13) (14) (15) (16) . However, the mechanism of signaling via uPAR, a glycolipid-anchored receptor that lacks a transmembrane signaling domain, and the identity of the adapter molecule(s) hypothesized to couple ligand binding to intracellular signaling remain elusive. Receptor binding also results in the activation of scuPA, the single-chain zymogen form of uPA, and initiates an extracellular proteolytic cascade that leads to the downstream activation of plasminogen and matrix metalloproteases (17, 18) . These enzymes remodel extracellular matrix (ECM) and the basal lamina associated with endothelial cells, and also release or activate various growth factors sequestered within the ECM such as vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), and transforming growth factor ␤ (19 -21) . The net result of this proteolytic flux combined with uPA-dependent intracellular signaling is acceleration of tumor cell invasion and tumorassociated angiogenesis.
The primary interaction of uPA with uPAR is mediated through the growth factor domain amino acids (aa) 1-48 of uPA. However, we have identified a second site in uPA that interacts with uPAR. This region, termed the connecting peptide, is comprised of aa 136 -143. Here we present data that a small, capped peptide derived from this region, Ac-KPSSPPEE-Am (Å6), inhibits the interaction of uPA with uPAR in a noncompetitive manner. Administration of this peptide to animals bearing experimental breast cancer tumors results in inhibition of tumor growth and metastasis in the absence of direct cytotoxic or anti-proliferative effects.
MATERIALS AND METHODS

Peptide synthesis
Å6 was synthesized by standard solid-phase methodology using p-methyl-benzhydrylamine resin and L-amino acids protected with the t-butyloxycarbonyl (BOC) group. Removal of the BOC group was with 50% trifluoroacetic acid in dichloromethane. Coupling was achieved with 1-hydroxybenzotriazole and dicyclohexylcarbodiimide. Side chain protection was 2-chlorobenzyloxycarbonyl for lysine, benzyl for serine, and cyclohexyl for glutamic acid. The amino-terminal lysine was capped by treatment with acetic anhydride. Deprotection and detachment of the completed peptide from the resin were accomplished by treatment with anhydrous hydrofluoric acid in the presence of anisole. High-pressure liquid chromatography on a Waters C18 preparative column using a 0 -40% linear gradient of 1.0% aqueous triethylamine phosphate into CH 3 CN gave fractions containing pure material that were reapplied to the column. The column was washed with 3 column volumes of 1.0% aqueous acetic acid and then eluted with a 0 -50% linear gradient of 1.0% aqueous acetic acid into CH 3 CN. Lyophilization afforded the Ͼ99% pure product as colorless, hygroscopic crystals easily soluble in water to Ͼ500 mM. Å7 (Ac-KPSSPPE-Am), Å8 (Ac-PSSPPEE-Am), Å10 (Ac-KPSSPPEELK-Am), and Å14 (Ac-KPSSPPEEL-Am) were prepared using similar methodology. For Å9 (NH 2 -KPSSPPEELK-COOH) and Å13 (NH 2 -KPSSP-PEE-COOH), the first amino acid was attached to the solidphase carrier through an ester linkage and the aminoterminal capping step was omitted.
Determination of Å6 dose for in vivo studies
Single administrations of Å6 up to 1500 mg/kg did not demonstrate any evidence of toxicity. A liquid chromatography/mass spectroscopy assay was developed to detect Å6 in plasma. Pharmacokinetic experiments demonstrated a short plasma half-life for Å6 (0.2 h) in mice. We initially attempted to achieve a plasma level at steady state (C SS ) that was at least equivalent to the in vitro IC 50 for tumor cell invasion (5-10 M). This objective was accomplished by delivering Å6 via continuous infusion using osmotic mini-pumps at a dose of 75 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 . We then compared administration of this dose by continuous infusion or by twice daily (bid) injections. Both protocols yielded identical anti-tumor results, indicating that the pharmacokinetics did not correlate with the antitumor activity of Å6 and that a steady-state plasma level of Å6 was not required for anti-tumor activity. For simplicity, the IP protocol was used for all subsequent studies.
Vehicle (phosphate-buffered saline, or PBS) was used as the control for in vivo studies since it is relevant to the therapeutic setting. Although scrambled peptides are useful for establishing specificity in vitro, they are completely different chemical entities and most likely have different behavior in vivo. Thus, they were not considered as controls for the animal studies.
Cells and cell culture
The rat mammary adenocarcinoma cell line Mat B-III was obtained from the American Type Culture Collection (ATCC, Rockville, Md.). Cells were maintained in culture in vitro in McCoy's 5A modified medium (Gibco BRL, Burlington, ON, Canada) supplemented with 10% fetal bovine serum (FBS), 25 mM 4-(2-hydroxyethy)-1-piperazineethanesulfonic acid, 26 mM sodium bicarbonate, 100 units/ml of penicillin-streptomycin sulfate (Gibco BRL), and 0.2% gentamicin (Sigma, St. Louis, Mo.).
Human breast adenocarcinoma cell line MDA-MB-231 was obtained from ATCC and maintained in L-15 medium (Gibco BRL) supplemented with 10% FBS, 100 units/ml of penicillin-streptomycin sulfate, and 0.2% gentamicin. MDA-MB-231-GFP (green fluorescent protein) cells were generated by transfecting the expression vector that contained the codonoptimized human GFP-S65T gene (Clontech Laboratories, Inc., Palo Alto, Calif.) using Lipofectin reagent (Gibco BRL). Cells with stably integrated plasmids were selected for neomycin resistant gene with geneticin (G418) (Gibco BRL).
Surface plasmon resonance
Binding kinetics of suPAR in the presence and absence of Å6 was measured using a BIA 3000 optical Biosensor (Biacore, AB, Sweden) (22) . This method detects binding interactions in real time by measuring changes in the refractive index (RI) at a biospecific surface, and enables association and dissociation rate constants to be calculated. For these studies, recombinant scuPA (a kind gift of Dr. Jack Henkin, Abbott Laboratories, Abbott Park, Ill.) was coupled to a B1-research grade sensor chip flow cells (Biacore, AB, Sweden) via a standard amine coupling procedure (23) using N-hydroxysuccinimide/N-ethyl-N- [3-(dimethylamino) propyl] carbodiimide hydrochloride (Pierce, Rockford, Ill.) at a level of 1000 RU each. Sensor surfaces were coated with ligands (10 g/ml) in 10 mM NaOAc buffer, pH 5.0. After immobilization, unre-acted groups were blocked with 1 M ethanolamine, pH 8.5. Binding buffer was PBS, pH 7.4, 0.005% TWEEN-20. Binding of suPAR (Ϯ Å6) was measured at 25°C at a flow rate of 100 l/min for 1 min, with 2 min of dissociation examined. The bulk shift due to changes in RI was measured using the suPAR surface and was subtracted from the binding signal at each condition to correct for nonspecific signals. Surfaces were regenerated with 2 ϫ 30 s pulses of 1 M NaCl, pH 3.3, followed by an injection of binding buffer for 1 min to remove this high-salt solution. All injections were performed in a random fashion using the RANDOM command in the automated method. Binding of suPAR was performed at 100 nM, 33.3 nM, 11.1 nM, 3.7 nM, and 1.24 nM in the absence or presence of 60 M, 20 M, 6.6 M, 2.2 M, 0.74 M, or 0.25 M Å6. Data were fit using a 1:1 Langmuir reaction mechanism using BIA evaluation 3.0 software (Biacore, AB, Sweden). Dissociation and association rates were calculated separately to examine the effect of Å6 on the affinity of suPAR to scuPA. Clot lysis assay was performed as described previously (24) .
Boyden chamber Matrigel invasion assay
The effect of Å6 on-treated Mat B-III and MDA-MB-231-GFP cells was determined by two compartment Boyden chambers (Transwell, Costar, Cambridge, Mass.) and basement membrane Matrigel invasion assay as described previously (25) . The 8 m pore polycarbonate filters were coated with basement membrane Matrigel (50 g/filter). Matrigel was then reconstructed by adding 0.1 ml serum-free culture medium to the upper chamber and incubated for 90 min. After removal of medium, cells (5ϫ10 4 ) in 0.1 ml of medium with or without Å6 was added to the upper chamber and placed in a lower chamber prefilled with 0.8 ml of serum-free medium supplemented with 25 g/ml fibronectin (Sigma, Oakville, ON, Canada) and incubated at 37°C for 24 h. At the end of incubation, medium was removed and filters were fixed in 2% paraformaldehyde, 0.5% glutaraldehyde (Sigma) in 0.1 M phosphated buffer, pH 7.4 at room temperature (RT) for 30 min. After washing with PBS, all filters were stained with 1.5% toluidine blue and filters were mounted onto glass slides. Cells were examined under a light microscope. Ten fields under 400ϫ magnification were randomly selected and the mean cell number was calculated.
Endothelial cell migration assay
Transwell (Costar, 8.0 m pore size) were coated with type I collagen (50 g/ml) by adding 200 l of the collagen solution per transwell, then incubating overnight at 37°C. The transwells were assembled in a 24-well plate and bFGF (1 ng/ml) was added to the bottom chamber in a total volume of 0.8 ml M199 containing 2% FBS. Human dermal microvascular endothelial cells were detached from monolayer culture using Verseen, centrifuged, and reconstituted in M199 containing 2% FBS (1ϫ10 6 cells/ml). 0.2 milliliters of this cell suspension was added to the upper chamber of each Transwell. Inhibitors to be tested were added to both the upper and lower chambers, and the migration was allowed to proceed for 5 h under 5% CO 2 in a humidified atmosphere at 37°C. The transwells were then removed from the plate and the upper chamber wiped clean with a cotton swab. Giemsa stain was used to fix and stain the cells, and the number of cells that had migrated to the bottom aspect of the membrane was counted. Data are presented as the average number of migrated cells per 10 fields.
Animal protocols
Inbred female Fischer 344 rats weighing 200 -220 g were obtained from Charles River Inc. (St. Constant, QC, Canada). Before inoculation, Mat B-III tumor cells grown in serumcontaining medium were washed with Hank's balanced buffer and trypsinized for 5 min. Cells were then collected in Hank's balanced buffer and centrifuged at 1500 rpm for 5 min. Cell pellets (1ϫ10 6 cells) were resuspended in 0.2 ml saline and injected using 1 ml insulin syringes into the mammary fat pad of rats anesthetized with ethanol/Somnotal (MTC Pharmaceuticals, Cambridge, ON, Canada). Control and experimental animals were injected intraperitoneally (i.p.) with PBS and Å6 (75 mg⅐kg Ϫ1 ⅐day Ϫ1 ) respectively twice a day for 16 days. All animals were numbered, kept separate, and examined for the development of tumors daily for up to 17 days. The tumor mass of control and experimental animals was measured in two dimensions by calipers and the tumor volume was calculated. Control and experimental animals were killed at the end of this study (day 17) and examined and scored for the development of macroscopic tumor metastases in various tissues. Primary tumor tissues were also removed from control and experimental animals for histological examination.
For xenograft studies, 4-to 6-wk-old BALB/c (nu/nu) female mice were obtained from Charles River Inc. Prior to inoculation, MDA-MB-231-GFP cells grown in serum containing culture medium were washed with Hank's balanced buffer and centrifuged at 1500 rpm for 5 min. Cell pellets (5ϫ10 5 cells/mice) were resuspended in 100 l of Matrigel (Becton Dickinson Labware, Mississauga, ON, Canada) and saline mixture (20% Matrigel) and injected into the mammary fat pads of the mice. All animals were numbered and kept separately in a temperature-controlled room on a 12 h/12 h light/dark schedule with food and water ad libitum. Tumors were allowed to grow to the size of 15-25 mm 3 prior to drug administration. At this time, animals were randomized into two groups. Å6 (75 mg⅐kg Ϫ1 ⅐day
Ϫ1
) and sterile PBS were injected i.p. twice a day into the two groups of mice, respectively. The tumor mass was measured in two dimensions with calipers twice a week. At the end of xenograft study, the mice were killed and their lungs, liver, spleen, and other organs were removed. These fresh tissues from control and experimental mice were sliced at ϳ1 mm thickness and observed directly under a fluorescence microscope. The number of tumor cells from 10 random sites was counted per field of examination and photographed.
Histology and immunohistochemistry
Primary tumors were fixed in 4% paraformaldehyde overnight, dehydrated, and embedded in paraffin (Fisher Scientific, Montreal, QC, Canada) the next day. Tumor sections (4 m) were deparaffinized, then rehydrated and stained with hematoxylin/eosin (H&E). For TUNEL assay, paraffin-embedded tissue sections were soaked in Toluene to deparaffinize, then rehydrated in graded alcohol series (100% to 70%). For enzyme predigestion of formalin-fixed tissue, the sections were incubated for 30 min at RT in 15 g/ml of proteinase K/10 mM Tris/HCl. The terminal deoxynucleotidyl transferase (Boehringer Mannheim, QC, Canada) diluted in TUNEL reaction mixture, was added to the slides and incubated at 37°C for 60 min. After rinsing with PBS, the sections were coated with 50 l of anti-fluorescein antibody conjugated with converter-POD (horseradish peroxidase) at 37°C for 30 min. For factor VIII staining enzyme predigestion of formalin-fixed tumors was done by incubation at 37°C in 0.1 g Pronase type 14/100 ml PBS, followed by washing in 10 mM PBS (pH 7.6). Anti-human endothelial cell antibody against factor VIII-related antigen (Von Willebrand factor) (DAKO Diagnostica Inc., Mississauga, Ontario, Canada) was used as primary antibody diluted in serum/PBS (1:600). Tumor sections were incubated for 60 min at RT, followed by further incubation for 30 min with biotinylated anti-rabbit link antibody (Zymed Laboratories Inc., San Francisco, Calif.). Sections were rinsed with PBS, followed by coating with streptavidin conjugated to horseradish peroxidase for 10 min. The substrate DAB was then incubated with TUNEL and factor VIII-related antigen sections for 10 min at RT (Sigma, Ontario, Canada). Finally, the sections were counterstained with hematoxylin and mounted. All histological examinations were carried out by light and fluorescence microscopy using a Nikon microscope equipped with a Xenon lamp power supply and a GFP filter set (Chromotechnology Corp., Brattleboro, Vt.). For quantitation of TUNEL-positive cells, three sections from each tumor were analyzed using NIH image version 1.61 and expressed as integrated density per field of examination. In control and Å6-treated tumors, microvessels were counted and expressed as angiogenesis density representing the mean of at least three areas with high vascularization in three different sections from each tumor. All slides were interpreted by two independent investigators (26) .
Statistical analysis
Results are expressed as the mean Ϯ se of at least triplicate determinations and statistical comparisons are based on Student's t test or analysis of variance. A probability value of Ͻ0.05 was considered to be significant.
RESULTS
Å6 inhibits scuPA-suPAR interaction
Binding of suPAR (soluble uPAR) to immobilized scuPA (single-chain uPA) was examined using a BIA 3000 optical biosensor in the absence or presence of Å6. Å6 inhibited the binding of 100 nM suPAR to scuPA in a dose-dependent manner at concentrations of Å6 as low as 0.25 M (Fig. 1A) . Similar results were observed at 33.3 nM and 11.1 nM suPAR (data not shown). The specificity of this inhibition was demonstrated by the lack of effect of Å29, an analog of Å6 in which the first serine is replaced by a glutamic acid (data not shown). This amino acid substitution was chosen because it mimics a phosphorylated serine at this position. Franco et al. (27) have described that high molecular weight uPA (HMW uPA) can be phosphorylated at this serine and that phosphorylated uPA is unable to mediate monocyte chemotaxis or adhesion, in contrast to unmodified uPA. Association and dissociation rate constants were calculated for suPAR binding to scuPA in the absence and presence of Å6 at the three highest concentrations of suPAR. The k d and the k a were calculated separately for each of 21 conditions and the data were fitted to a 1:1 Langmuir model. Langmuir isotherms in the absence and presence of Å6 were not parallel, suggesting that Å6 did not inhibit the suPAR-scuPA interaction in a competitive manner (data not shown). The K d of suPAR was 1 nM and 1.7 nM in the absence and presence of Å6, respectively, whereas the R max decreased in a dosedependent manner (Fig. 1B, 100 nM suPAR) . The Ϫ7 M), as would be expected for a competitive inhibitor. These data are consistent with Å6 inhibiting the suPAR-scuPA interaction in a noncompetitive, allosteric manner.
Additional evidence for the allosteric inhibition of the scuPA-suPAR interaction by Å6 was derived from the finding that Å6 inhibits plasminogen activation by the scuPA-suPAR complex in a clot lysis assay (28) . The plasminogen-activating activity of this complex has been hypothesized to result from a conformational change in the complex that leads to the formation of an active site in the absence of conversion to two-chain uPA (tcuPA) (28). Å6 did not inhibit clot lysis initiated by tcuPA (data not shown). However, Å6 almost completely abrogated clot lysis mediated by the scuPA-suPAR complex whereas the control peptide Å29 had no such effect (Fig. 1C) .
Å6 inhibits breast cancer cell invasion and endothelial cell migration in vitro
Tumor cell invasion and endothelial cell migration during angiogenesis are key events that contribute to tumor progression. The uPA-uPAR system has been demonstrated to play a major role in both processes. Since Å6 inhibited the interaction of suPAR with scuPA, we assessed its ability to inhibit cell invasion and migration in vitro. Peptides of different length based on the connecting peptide region of uPA (aa 136 -158) were prepared and tested for their ability to inhibit MDA-MB-231 tumor cell invasion in vitro. Of all the peptides tested, only Å6 was able to inhibit tumor cell invasion in this assay ( Fig. 2A) . Uncapped versions of Å6 also had no activity, indicating that Å6 represented the minimal active epitope of the connecting peptide, at least from the standpoint of invasion (Fig. 2A) . The dose dependence of Å6 inhibition of rat and human breast cancer cell invasion was evaluated in a Boyden chamber invasion assay. Å6 decreased the number of rat and human breast cancer cells invading through Matrigel with an IC 50 between 5-25 M for both cell lines tested (Fig.   2B, C) . Invasion was not inhibited further at Å6 concentrations greater than 50 M. In contrast to molecules that inhibit the binding of the GFD (aa 1-48) of uPA to uPAR (29) , the ability of Å6 to inhibit invasion did not appear to be species specific. Finally, Å6 also inhibited the migration of human dermal microvascular endothelial cells on type I collagen (Fig. 2D) . The IC 50 for endothelial cell migration (25-50 M) was slightly higher than that observed in the tumor cell invasion assay.
Å6 blocks rat breast cancer growth and metastasis in vivo
Since the uPA-uPAR system contributes to the invasion and motility of multiple cell types associated with tumor progression (e.g., tumor cells, endothelial cells), we hypothesized that the inhibition of the uPA-uPAR interaction using Å6 would have significant anti-tumor effects in vivo. We expected that a capped peptide would be less susceptible to exoprotease degradation in the plasma (although this was not specifically tested) and would therefore have a half-life sufficient to provide efficacy in vivo. Rat Mat B-III breast cancer cells (1ϫ10 6 cells) were inoculated into the mammary fat pads of female Fischer rats. Å6 treatment (75 mg⅐kg Ϫ1 ⅐day Ϫ1 ) was initiated on the same day as the inoculation and continued for 16 days. Tumor volumes were determined daily and compared to the control group, which received vehicle alone. Infusion of Å6 resulted in a marked decrease (55%) in tumor volume throughout the course of this study (Fig. 3A) . Control and Å6-treated animals were killed on day 17 and evaluated for the presence of macroscopic tumor metastases. Control animals, receiving vehicle alone, developed macroscopic tumor metastases to lungs, retroperitoneal and axillary lymph nodes. In contrast, all Å6-treated animals exhibited significantly fewer or no macroscopic tumor metastases at these sites (Fig. 3B) .
Å6 blocks human breast cancer growth and metastasis in vivo
We then examined the anti-tumor effects of Å6 in a xenograft model of human breast cancer. To facilitate the detection of metastatic tumor cells, we first transfected human breast cancer cells (MDA-MB-231) with the cDNA for green fluorescent protein (MDA-MB-231-GFP). MDA-MB-231 and MDA-MB-231-GFP cells exhibited no significant difference in their invasive capacity in a Matrigel invasion assay (data not shown). For in vivo studies, MDA-MB-231-GFP cells (5ϫ10 5 ) were coinoculated into the mammary fat pads of female BALB/c (nu/nu) mice with Matrigel. Tumors were allowed to grow until palpable (15-25 mm 3 , ϳ4 wk after inoculation), at which time Å6 administration was initiated. Animals received Å6 (75 mg⅐kg Ϫ1 ⅐day Ϫ1 ) or vehicle alone for 6 wk and tumor volumes were determined at weekly intervals. Administration was discontinued after 6 wk and the animals were killed and evaluated at the end of week 7. Å6 administration resulted in a significant (-90%) decrease in the primary tumor volume (Fig.  3C) , which was clearly evident upon visual inspection of the dead animals (Fig. 3D) . Necropsy examination revealed that control animals receiving vehicle alone routinely developed a large number of macroscopic tumor metastases in the lungs and axillary lymph nodes. In contrast, Å6 treatment resulted in significantly fewer and smaller metastases to lymph nodes and a trend to decreased macroscopic metastases to lungs (Fig. 3E) . We also evaluated the number of microscopic tumor foci present in other organs (liver, lungs, and spleen). Microscopic dissemination was observed only in these organs, and the number of metastatic tumor cells was significantly lower in the liver and lungs of Å6-treated animals when compared to vehicle controls (Fig. 3F) . No significant difference in the number of disseminated tumor cells was observed in the spleens of control and Å6-treated group of animals.
Å6 treatment leads to extensive tumor necrosis
Necrotic cores are often observed in rapidly growing experimental tumors, and we observed this in both the syngeneic (Mat B-III) and the xenograft (MDA-MB-231-GFP) models. Although tumor core necrosis (ϳ20% of the total tumor volume) might be expected to occur as a result of hypoxia, this is not the case at the periphery of the tumors. The periphery of primary Mat B-III control tumors appeared predominantly viable when assessed by H&E staining (Fig.  4a) . In contrast, H&E staining of sections from Å6-treated tumors revealed large areas of hemorrhagic necrosis (in this context, necrosis is used to describe tumor cell death regardless of the mechanism or pathway involved in that process), which comprised greater than 75% of the peripheral tumor area (Fig. 4b) . TUNEL staining of tumor sections revealed very few TUNEL-positive cells in sections obtained from control Mat B-III tumors (Fig. 4c) . However, sections obtained from Å6-treated tumors revealed extensive positive staining by TUNEL (Fig.  4d) . TUNEL-positive foci were significantly more numerous in Å6-treated animals and were observed in both necrotic and non-necrotic regions, suggesting that one mechanism that could be responsible for cell death was apoptosis (Fig. 4, bottom) . Å6 treatment of tumor cells did not inhibit proliferation or directly lead to apoptosis in vitro (data not shown). Similar results were also observed in sections obtained from MDA-MB-231-GFP xenograft tumors (data not shown). Effect of Å6 on tumor growth and metastases. Mat B-III tumor-bearing female Fischer rats were injected i.p. with Å6 or vehicle alone for 16 days. Tumor volume in control (CTL) and experimental (Å6) animals was determined at timed intervals (A). At day 17 post-tumor inoculation, animals were killed and the total number of macroscopic metastatic foci was counted (B). MDA-MB-231-GFP tumor-bearing BALB/c (nu/nu) mice were injected i.p. with Å6 or vehicle alone (CTL) and tumor volume was determined at weekly intervals (C). After 6 wk of treatment, gross tumor mass was compared in control (CTL) and Å6-treated animals (D). E) At the end of this study, control and experimental mice were killed to count the number of macroscopic tumor foci. Fluorescent tumor cells in control and Å6 tissues were also counted under a microscope (E). A representative photomicrograph of each organ from control (CTL) and Å6-treated animals (Å6) from three such experiments is shown (F ). Results represent the mean Ϯ se of 6 starting animals in each group in 4 different experiments. Significant difference from control tumor-bearing animals after treatment with Å6 is denoted by asterisks (PϽ0.05).
Å6 treatment results in decreased tumor vessel hot spots
Based on the ability of Å6 to inhibit endothelial cell migration in vitro, we decided to evaluate whether Å6 had any effect on tumor vessel formation in vivo. We used anti-factor VIII-related antigen to stain both rat and mouse blood vessels in our respective models. Sections from Å6-treated tumors had significantly less factor VIII-positive hot spots than sections from control Mat B-III tumors (Fig. 5) . Similar results were observed in sections obtained from the MDA-MB-231-GFP xenograft model (data not shown).
DISCUSSION
The urokinase plasminogen activator system has pleiotropic roles in tumor growth, angiogenesis, and metastasis. Initial studies of the role of this system in tumor progression focused on the proteolytic cascades initiated by uPA, mediated by the catalytic B chain, which resulted in matrix remodeling and allowed for the invasion of tumor cells and the migration of endothelial cells. More recently, signaling cascades mediated by the binding of uPA to uPAR via the GFD have been described, although their role in tumor progression is thus far poorly understood.
In this report, we describe the activity of a peptide, Å6, derived from the connecting peptide region of uPA that is capable of inhibiting both of these cascades simultaneously through its inhibition of the uPA-uPAR interaction. Since Å6 is derived from the connecting peptide (aa 136 -143) of uPA, it suggests that this region of uPA may represent a novel epitope involved in the uPA-uPAR interaction. Franco et al. (27) recently demonstrated that Ser-138 (corresponding to Ser-3 in the Å6 sequence) is phosphorylated in HMW uPA and that this phosphorylation abrogates the ability of phosphorylated HMW uPA to mediate monocyte chemotaxis. From the standpoint of drug development, Å6 is especially intriguing since it apparently inhibits the uPA-uPAR interaction in an allosteric manner, perhaps by altering or stabilizing a particular conformation of one or both of these proteins. Å6 does not inhibit the growth of any cell line tested thus far in vitro, including tumor and endothelial cells. However, despite this lack of direct cytotoxic or anti-proliferative activity, Å6 treatment leads to a striking suppres- sion of tumor growth and metastasis in several animal models using breast cancer cell lines.
Å6 inhibits the tumor growth of the MDA-MB-231 cells to a greater extent than the Mat B-III cells in vivo. Mat B-III tumors grow much faster than the MDA-MB-231 tumors in vivo and may overcome the inhibitory effects of Å6. Our data suggest that Å6 maintains tumor dormancy, and a rapidly proliferating tumor such as the Mat B-III might overcome this suppressive effect much more rapidly than a more indolent tumor such as the MDA-MB-231. This seems to be an emerging paradigm for anti-angiogenic agents when they are used as monotherapy in preclinical models, as no single anti-angiogenic agent (including angiostatin and endostatin) is able to reduce tumor burden once tumors have reached 100 mm 3 (30) The MDA-MB-231 model may be more relevant to human disease as most human solid tumors (including breast) are not highly proliferative. We also present in vitro data on the ability of Å6 to inhibit tumor cell invasion and human endothelial cell migration, and the differences observed with Å6 treatment in vivo could reflect species specificity. The high-affinity binding of uPA to uPAR (via its growth factor domain) is species specific and the affinities of the uPA for uPAR across species (for example, human uPA binding to rat uPAR) differ by at least two orders of magnitude. However, Å6 may represent a secondary, weaker affinity interaction between uPA and uPAR that modulates conformation rather than direct binding, and it is not known whether this interaction is species specific. In addition, our data on the effects of Å6 on the uPA-uPAR interaction have only been obtained using pure proteins and have not been extended to cell systems. Therefore, the activity of Å6 against tumor cells or endothelial cells could occur via some non-uPARdependent mechanism as well.
Å6 is derived from the human uPA sequence, and the corresponding sequences from rat and mouse are KPSSTVDQ and KPSSSVDQ. Since the KPSS is conserved in all species, it is tempting to speculate that this may represent the biologically active sequence of the peptide. We demonstrate in Fig. 2A that deletion of the amino-terminal lysine abolished the anti-migratory effect of Å6, indicating that the correct amino-terminal amino acid is important for the activity of Å6. However, similar results were also observed when the carboxyl-terminal amino acid was removed. The carboxyl-terminal amino acid is semiconserved (Gln in rat and mouse and Glu in human) and perhaps this is sufficient to maintain activity of the peptide. However, it is difficult to draw conclusions regarding species specificity based on the data presented in this report without knowing the contribution of each amino acid to activity.
Å6 may inhibit metastasis in several interdependent ways. Inhibition of tumor growth may lead directly to decreased metastasis simply through a reduction in tumor burden. Smaller tumors may be less vascularized, affording less opportunity for hematogenous dissemination. Å6 may also directly suppress the outgrowth of disseminated tumors cells once they have seeded. Disseminated tumor foci also depend on angiogenesis to survive and proliferate. The anti-angiogenic effects of Å6 described below could suppress the ability of small tumor foci to recruit blood vessels necessary for survival. The inhibition of metastasis by Å6 could also result from direct anti-invasive effects on the tumor cells themselves. The ability of tumor cells to invade depends on multiple cellular activities such as mobility, adhesion, and cytoskeletal reorganization occurring in a temporally organized manner. Since Å6 is able to inhibit the invasion of tumor cells in vitro, it may interfere with one or more of these activities in vivo as well.
Our data also demonstrate that Å6 also has antiangiogenic activity resulting in substantially less factor VIII-positive hot spots in sections obtained from Å6-treated animals. The effects of Å6 on vascular contractility and signaling have also recently been demonstrated by Haj-Yehia et al. (31) , suggesting another possible hypothesis to explain the activity of Å6. The inhibitory effects of Å6 on vascular contractility may impede blood flow to the tumor in addition to its effects on angiogenesis. Tumor neovessels, which are prone to collapse and occlusion, may be especially susceptible to an agent, such as Å6, that dysregulates vascular tone. Aggressive, rapidly growing tumors contain large zones of hypoxic cells. Low oxygen tension results in the up-regulation of both vasoconstricting (e.g., endothelin-1) as well as angiogenic (VEGF, PDGF) growth factor expression by endothelial cells (28) . Hypoxia has been implicated as a catalyst for the initiation of tumor angiogenesis (32) and may mediate both new vessel formation (long term effect) as well as local vascular contractility within a tumor. The fact that Å6 antagonizes the activity of vasoconstricting agents such as phenylephrine and endothelin-1 suggests that part of its antitumor effects may result from a suppression of hypoxia-dependent pathways of angiogenesis in addition to the inhibition of vessel formation. Further, Å6 does not seem to affect nonstimulated vessels as no effects on vasoconstriction were observed by Haj-Yehia et al. (31) in the absence of vasoconstricting stimuli. Experiments are currently under way to examine the effects of Å6 on the expression of hypoxia-related genes and the initiation of angiogenesis in tumors (angiogenic switch). This hypothesis is consistent with the data observed in tumor models in which Å6 treatment must be started before a tumor reaches a certain critical size, after which time angiogenesis has already initiated and Å6 treatment alone is no longer sufficient to inhibit tumor progression.
The inhibition of vessel formation through either an anti-angiogenic or an anti-vascular mechanism of action could also lead to increased tumor cell death through apoptosis or related mechanisms. Clinical agents (e.g., combretastatin) that disrupt tumor blood flow have demonstrated potent anti-tumor effects leading to tumor cell death (33) . Despite extensive TUNEL staining in sections derived from Å6-treated tumors, we cannot conclude that this represents apoptosis since any process that leads to DNA fragmentation would also result in TUNELpositive staining. Nevertheless, the fact that tumor cell death (histological examination of tissues obtained from Å6-treated animals revealed no evidence of toxicity or nontumor necrosis) occurs in the absence of any direct cytotoxic effects points to modulation of the tumor microenvironment by Å6 as one likely aspect of its mechanism of action.
We are currently in the process of identifying more potent analogs of Å6. These will be used to further elucidate the molecular basis of the antitumor effects described in this manuscript. The effect of an allosteric inhibitor such as Å6 cannot be competed away by ligand, making such a compound especially useful for inhibiting receptor-ligand interactions such as the binding of uPA to uPAR. 
